Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by and educational grant from AstraZeneca.

Molecular Tumor Board in EGFR Mutation–Positive Lung Cancers: Integrating Clinical Data Into Patient Care

Molecular Tumor Board in EGFR Mutation–Positive Lung Cancers: Integrating Clinical Data Into Patient Care


Monday, April 1, 2019
6:30 PM – 7:00 PM Registration & Dinner
7:00 PM - 9:00 PM Program

Atlanta Hyatt Regency
International North and South
265 Peachtree St NE
Atlanta, GA 30303

Molecular Tumor Board in EGFR Mutation–Positive Lung Cancers Overview:

Molecular Tumor Board in EGFR Mutation–Positive Lung Cancers: Integrating Clinical Data Into Patient Care is a live symposium to be held adjunct to the AACR annual meeting in Atlanta. Diagnosis, molecular testing, treatment decision-making, and sequencing in the management of patients with advanced, epidermal growth factor receptor (EGFR) mutation–positive non–small cell lung cancer (NSCLC) continues to change as new evidence emerges. The development of next-generation agents and new molecular testing modalities make it imperative that all members of the multidisciplinary care team understand both the new data and best practices to practically apply EGFR inhibitors to patient care, including methods that proactively plan to manage and mitigate treatment-related toxicities.

To meet these educational needs, this cutting-edge symposium will explore considerations in first-line therapy, including scenarios with de novo resistance mutations; approaches to managing resistance to therapy, including the role of molecular testing; and managing central nervous system (CNS) metastases. This activity will provide you with the opportunity to learn from a panel of world-class experts in lung cancer who will review recent practice-changing data and state-of-the-art approaches for patients with EGFR mutation–positive NSCLC, with an emphasis on examining the evidence and trial data, and how to interpret and apply those data in your practice. Be sure to join us in Atlanta for expert advice on optimal treatment paradigms for patients with NSCLC and EGFR mutations. This is a symposium that you won’t want to miss!

Benefits of attending Molecular Tumor Board in EGFR Mutation–Positive Lung Cancers: Integrating Clinical Data Into Patient Care:

  • Gain insights into the use of liquid-based and tissue-based testing methods to choose the best therapy for patients with EGFR mutation–positive NSCLC
  • Learn about the latest clinical data on first-line treatment of patients with NSCLC and EGFR mutations
  • Expand knowledge of approaches to manage patients whose disease progresses on EGFR inhibitor therapy
  • Develop strategies to manage treatment-related toxicities in patients with EGFR mutation–positive NSCLC

Acknowledgment of Commercial Support

This activity is supported by and educational grant from AstraZeneca.

Target Audience

This educational program is directed toward the AACR audience, including medical oncologists and cancer researchers. Other healthcare professionals involved in the study or treatment of cancer will also be invited to participate.  

Learning Objectives

Upon successful completion of this activity, oncologists who attend should be better prepared to:

  • Evaluate liquid biopsies and other molecular testing approaches to optimize selection in the first-line setting and subsequent lines of therapy for patients with advanced NSCLC
  • Describe key clinical data informing initial treatment of patients with EGFR mutation–positive NSCLC
  • Assess clinical data regarding the management of acquired resistance and disease progression in patients with EGFR mutation–positive NSCLC
  • Discuss interventions for patients with EGFR mutation–positive NSCLC and CNS metastases and/or treatment-related adverse events

Registration

2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
 
Registration Fee - Free

Please note that attendance is on a first-come, first-served basis. Please arrive early to ensure your spot!

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.    

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Program Chair for Molecular Tumor Board in EGFR Mutation–Positive Lung Cancers

David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA




Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
30
Filter By